Category: esters-buliding-blocks

On October 1, 2015, Lin, Wenbin; Manna, Kuntal; Zhang, Teng published a patent.Synthetic Route of 1312703-30-2 The title of the patent was Preparation of metal-organic frameworks containing nitrogen-donor ligands for efficient catalytic organic transformations. And the patent contained the following:

Metal-organic framework (MOFs) compositions based on nitrogen donor-based organic bridging ligands, including ligands based on 1,3-diketimine (NacNac), bipyridines and salicylaldimine, were synthesized and then post-synthetically metalated with metal precursors, such as complexes of first row transition metals. Metal complexes of the organic bridging ligands could also be directly incorporated into the MOFs. The MOFs provide a versatile family of recyclable and reusable single-site solid catalysts for catalyzing a variety of asym. organic transformations. The solid catalysts can also be integrated into a flow reactor or a supercritical fluid reactor. For example, complex MOF [Zr6(OH)4O4L6] (bpy-UiO) (H2L = 2,2′-bipyridine-5,5′-dicarboxylic acid) is synthesized by reaction of ZrCl4 and H2L in DMF. The complex is used as catalyst for C-H borylation of arenes. Gas adsorption of the complex is measured as well. The experimental process involved the reaction of Dimethyl 2′-amino-[1,1′:4′,1”-terphenyl]-4,4”-dicarboxylate(cas: 1312703-30-2).Synthetic Route of 1312703-30-2

The Article related to transition metal oxo hydroxy bipyridinedicarboxylato complex catalyst preparation, gas adsorption transition metal oxo hydroxy bipyridinedicarboxylato complex, crystal structure transition metal oxo hydroxy bipyridinedicarboxylato complex, silylation hydrogenation catalyst transition metal oxo hydroxy bipyridinedicarboxylato complex and other aspects.Synthetic Route of 1312703-30-2

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Xiong, Chenghe; Feng, Shaojie; Qiao, Yin; Guo, Zhongwu; Gu, Guofeng published an article in 2018, the title of the article was Synthesis and Immunological Studies of Oligosaccharides that Consist of the Repeating Unit of Streptococcus pneumoniae Serotype 3 Capsular Polysaccharide.Synthetic Route of 79642-50-5 And the article contains the following content:

A highly convergent and efficient strategy was developed for the chem. synthesis of complex oligosaccharides of Streptococcus pneumoniae type 3 capsular polysaccharides that contain multiple glucuronic acid units. Once the oligo-glucosides were efficiently and stereoselectively assembled, the designated glucose units were regioselectively oxidized to glucuronic acid in one step at the final synthetic stage, which helped avoid difficult glycosylation that involved glucuronic acid. The target oligosaccharides had a free amino group at the reducing terminus and varied caps at the non-reducing terminus to enable further modification and structure-activity relationship studies. Immunol. evaluations of the oligosaccharide-tetanus toxoid conjugates showed that they elicited robust T-cell-dependent IgG antibody responses and that the sugar chain length had a major impact on their immunol. properties. In particular, the penta- and hexasaccharides were identified as promising antigens for vaccine development. The experimental process involved the reaction of Bis(2,5-dioxopyrrolidin-1-yl) glutarate(cas: 79642-50-5).Synthetic Route of 79642-50-5

The Article related to bovine serum albumin tetanus toxoid glucuronic acid oligosaccharide preparation, structure activity igg antibody glycosylation glucuronic acid oligosaccharide, igg antibody vaccine tetanus toxoid glycosylation glucuronic acid oligosaccharide, oligosaccharide preparation immunol repeating unit streptococcus pneumoniae polysaccharide and other aspects.Synthetic Route of 79642-50-5

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On May 3, 2019, Bhardwaj, Monika; Rasool, Faheem; Tatina, Madhu Babu; Mukherjee, Debaraj published an article.Computed Properties of 2873-29-2 The title of the article was Construction of Fused Oxabicyclic Scaffolds from Glycals and Styrenes via One-Pot Domino Transformations. And the article contained the following:

Glycals underwent diastereoselective cascade ring opening and cyclocondensation reactions with styrenes in the presence of TfOH in CH2Cl2 to yield arylcyclopentenofurans such as I. When either benzene or toluene was used as solvent, glycals underwent diastereoselective cascade Ferrier C-glycosylation and double Friedel-Crafts reactions with styrenes in the presence of TfOH to yield arylnaphthopyrans (oxadecalins) such as II. The mechanism of the reaction of triacetoxy-D-glucal with styrene in benzene was studied by isolation of intermediates and by determination of the deuterium kinetic isotope effect which provided evidence for the C-glycosylation as the slow step in the reaction. A mechanism for the reactions is proposed. The experimental process involved the reaction of (2R,3S,4R)-2-(Acetoxymethyl)-3,4-dihydro-2H-pyran-3,4-diyl diacetate(cas: 2873-29-2).Computed Properties of 2873-29-2

The Article related to arylcyclopentenofuran arylnaphthopyran diastereoselective nonracemic preparation, triflic acid catalyst ring opening cyclocondensation glycosylation styrene glycal, stereoselective tandem ring opening cyclocondensation styrene glycal dichloromethane solvent, tandem ferrier glycosylation friedel crafts reaction styrene glycal arene and other aspects.Computed Properties of 2873-29-2

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On March 24, 1993, Gilbert, Kevin; Williams, Peter D.; Hobbs, Doug W.; Evans, Ben E.; Veber, Daniel F. published a patent.Electric Literature of 53838-27-0 The title of the patent was Preparation of hydantoin and succinimide-substituted spiroindanylcamphorsulfonyl derivatives as oxytocin and vasopressin antagonists. And the patent contained the following:

Title compounds [I; R = substituted (unsaturated) 5- or 6-membered heterocyclyl containing 1-3 of N, O, or S], were prepared as oxytocin antagonists (no data). Thus, indene in THF was treated with LiN(SiMe3)2 and then with (ClCH2CH2)2NCO2CMe3 (preparation given) to give 1′-(tert-butoxycarbonyl)spiro(indene-1,4-piperidine), which was deprotected and acylated with (+)-10-comphorsulfonyl chloride followed by oximation and reduction with H2/Raney Ni to give endo-I (R = NH2). This was treated with 4-nitrophenyl chloroformate/Et3N, then with H-His-OMe.2HCl/Et3N, and finally with NaH in EtOH to give I (R = Q). The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Electric Literature of 53838-27-0

The Article related to bicycloheptylmethylsulfonylspiroindanepiperidine oxytocin antagonist, spiroindanepiperidine bicycloheptylmethylsulfonyl preparation, preterm labor prevention spiroindenepiperidine, dysmenorrhea treatment spiroindanepiperidine, vasopressin antagonist spiroindanepiperidine, hydantoin spiroindanylcamphorsulfonyl oxytocin antagonist and other aspects.Electric Literature of 53838-27-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On August 3, 2006, Sekiguchi, Yoshinori; Kuwada, Takeshi; Hayashi, Masato; Nozawa, Dai; Amada, Yuri; Shibata, Tsuyoshi; Yamamoto, Shuji; Ohta, Hiroshi; Okubo, Taketoshi; Koami, Takeshi published a patent.Related Products of 141940-37-6 The title of the patent was Preparation of 1,3-dihydro-2H-indol-2-one compounds and pyrrolidin-2-one compound fused with aromatic heterocycle as antagonists of arginine-vasopressin V1b receptor. And the patent contained the following:

The title compounds [I; ring A = each (un)substituted C6-14 aryl or aromatic heterocyclyl; P = a single bond, C1-5 alkylene; Q = each (un)substituted C6-14 aryl or aromatic heterocyclyl, Q1; RD and RE at 2 and 3 or 3 and 4 positions together form (un)substituted C1-3 alkylenedioxy, (CH2)m-O, N-(un)substituted (CH2)m-NH or NH-(CH2)m, (CH2)m-S, O-(CH2)m-S, or S-(CH2)m-S (m = 2-4); R5 = Q2, Q3, etc.; R6 = H, halo, (un)substituted HO; R7 = H, halo, (un)substituted SH; or R6 and R7 together represent oxo; R9 = each (un)substituted OH, SH or NH2; R33 = H, (un)substituted C1-5 alkyl, C3-8 cycloalkyl, C1-5 alkoxycarbonyl, C6-14 aryl, heterocyclyl; RA, RB, RC = H, halo, NO2, NH2, hydroxyamino, C1-5 alkyl, C1-5 alkoxy, C1-5 alkylthio, etc.] or pharmacol. acceptable salts thereof are prepared These compounds are highly selectively antagonistic to arginine-vasopressin V1b receptor over arginine-vasopressin V1a receptor and arginine-vasopressin V2 receptor, have high metabolic stabilities and show favorable migration into the brain and high concentrations in the plasma. They provide drugs which are efficacious against pathol. conditions relating to arginine-vasopressin V1b receptor. More particularly speaking, they provide drugs which have a therapeutic or preventive effect on depression, anxiety, Alzheimer’s disease, Parkinson’s disease, Huntington’s chorea, eating disorders, hypertension, digestive diseases, drug addiction, epilepsy, brain infarction, brain ischemia, brain edema, head injury, inflammation, immune diseases, alopecia and so on. Thus, reductive amination of (4R)-1-((3R)-5-Chloro-3-[2-methoxy-5-(2-oxoethyl)phenyl]-1-([4-methoxy-2-(trifluoromethoxy)phenyl]sulfonyl)-2-oxo-2,3-dihydro-1H-indol-3-yl)-4-hydroxy-N,N-dimethyl-L-prolinamide with piperidine using sodium triacetoxyborohydride in the presence of acetic acid din a mixture of THF and CHCl3 gave (+)-(4R)-1-[5-Chloro-3-[5-[2-(dimethylamino)ethyl]-2-methoxyphenyl]-1-[[4-methoxy-2-(trifluoromethoxy)phenyl]sulfonyl]-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-L-prolinamide (II). II inhibited the binding of [3H](Arg8)vasopressin to human arginine vasopressin V1b, V1a, and V2 receptor with IC50 of 0.32, 102, and 5,050, nM, resp. The experimental process involved the reaction of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate(cas: 141940-37-6).Related Products of 141940-37-6

The Article related to phenylsulfonylindolylprolinamide preparation antagonist arginine vasopressin v1b receptor, dihydroindolone preparation antagonist arginine vasopressin v1b receptor, pyrrolidinone fused heterocycle preparation antagonist arginine vasopressin v1b receptor, depression anxiety alzheimer disease treatment dihydroindolone preparation and other aspects.Related Products of 141940-37-6

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Sartorius, Frank; Trebing, Marc; Brueckner, Charlotte; Brueckner, Reinhard published an article in 2017, the title of the article was Reducing Diastereomorphous Bis(phosphane oxide) Atropisomers to One Atropisomerically Pure Diphosphane: A New Ligand and a Novel Ligand-Preparation Design.Application of 3976-69-0 And the article contains the following content:

1,1′-Biphenyl-2,2′-diphosphines with an achiral bridge spanning C-5 and C-5′ form atropisomers that are enantiomers. Accessing them in an atropisomerically pure form requires resolving a racemic mixture thereof or of a bis(phosphine oxide) precursor. 1,1′-Biphenyl-2,2′-diphosphines with a homochiral bridge spanning C-5 and C-5′ form atropisomers that are diastereomers. Synthesized the first compound of this kind (1) atropselectively and (2) under thermodn. control-seemingly a first-time exploit in diphosphine synthesis. The selectivity-inducing step was a high-temperature reduction of two non-interconverting bis(phosphine oxide) atropisomers (60:40 mixture). It furnished the desired diphosphine atropisomerically pure (and atropconvergently because the yield was 67 %). This diphosphine proved worthwhile in Tsuji-Trost allylations, the Hayashi addition of phenylboronic acid to cyclohexenone, and the asym. hydrogenation of Me acetoacetate (up to 95 % yield and 95 % ee). The experimental process involved the reaction of (R)-Methyl 3-hydroxybutanoate(cas: 3976-69-0).Application of 3976-69-0

The Article related to diastereomorphous phosphine oxide atropisomer atropisomerically pure diphosphine ligand design, biphenyl diphosphine atropisomer preparation catalyst tsuji trost allylation, hayashi addition phenylboronic acid cyclohexenone biphenyl diphosphine catalyzed, asym hydrogenation methyl acetoacetate biphenyl diphosphine catalyzed and other aspects.Application of 3976-69-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Schaate, Andreas; Roy, Pascal; Godt, Adelheid; Lippke, Jann; Waltz, Florian; Wiebcke, Michael; Behrens, Peter published an article in 2011, the title of the article was Modulated Synthesis of Zr-Based Metal-Organic Frameworks: From Nano to Single Crystals.SDS of cas: 1312703-30-2 And the article contains the following content:

The authors present a study on the influence of benzoic acid, acetic acid, and water on the syntheses of the Zr-based metal-organic frameworks Zr-bdc (UiO-66), Zr-bdc-NH2 (UiO-66-NH2), Zr-bpdc (UiO-67), and Zr-tpdc-NH2 (UiO-68-NH2) (H2bdc: terephthalic acid, H2bpdc: biphenyl-4,4′-dicarboxylic acid, H2tpdc: terphenyl-4,4”-dicarboxylic acid). By varying the amount of benzoic or acetic acid, the synthesis of Zr-bdc can be modulated. With increasing concentration of the modulator, the products change from intergrown to individual crystals, the size of which can be tuned. Addition of benzoic acid also affects the size and morphol. of Zr-bpdc and, addnl., makes the synthesis of Zr-bpdc highly reproducible. The control of crystal and particle size is proven by powder XRD, SEM and dynamic light scattering (DLS) measurements. TGA and Ar sorption experiments show that the materials from modulated syntheses can be activated and that they exhibit high sp. surface areas. Water proved to be essential for the formation of well-ordered Zr-bdc-NH2. Zr-tpdc-NH2, a material with a structure analogous to that of Zr-bdc and Zr-bpdc, but with the longer, functionalized linker 2′-amino-1,1′:4′,1”-terphenyl-4,4”-dicarboxylic acid, was obtained as single crystals. This allowed the 1st single-crystal structural anal. of a Zr-based metal-organic framework. The experimental process involved the reaction of Dimethyl 2′-amino-[1,1′:4′,1”-terphenyl]-4,4”-dicarboxylate(cas: 1312703-30-2).SDS of cas: 1312703-30-2

The Article related to zirconium terephthalate aminoterephthalate biphenyldicarboxylate aminoterphenyldicarboxylate mof preparation structure morphol, surface property zirconium terephthalate aminoterephthalate biphenyldicarboxylate aminoterphenyldicarboxylate mof, crystal structure zirconium aminoterphenyldicarboxylate oxo hydroxo mof complex and other aspects.SDS of cas: 1312703-30-2

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On June 3, 2010, Mochizuki, Akiyoshi; Nagata, Tsutomu; Kishida, Masanori; Takano, Daisuke; Kanno, Hideyuki published a patent.Electric Literature of 114312-57-1 The title of the patent was Preparation of N-(2-acylaminobenzyl or 2-acylaminoheterocyclylmethyl)thiophene-2-carboxamide derivatives as antithrombotics. And the patent contained the following:

Diamides represented by the general formula [I; ring A = benzene, pyridine, pyridazine, pyrazine, or pyrimidine ring; R1 = H, halo, C1-6 alkyl, halo-C1-6 alkyl, HO, C1-6 alkoxy, halo-C1-6 alkoxy; R2 = H, halo, C1-6 alkyl, halo-C1-6 alkyl, HO, C1-6 alkoxy, halo-C1-6 alkoxy, C1-6 alkylsulfonyloxy, cyano, CO2H, C1-6 alkoxycarbonyl, carboxy-C1-6 alkyl, each (un)substituted CONH2 or NH2, , etc.; T1 = CONR3, NR3CO; R3 = H, C1-6 alkyl; T2 = CR4R5NHCO; R4, R5 = H, C1-6 alkyl; Q1 = C1-6 alkylsulfonylphenyl, N,N-di(C1-6 alkyl)aminocyclohexyl, 2-oxopyrrolidinyl, 2-oxo[1,3]oxazolidinyl, 1,1-dioxo-1λ6-isothiazolidinyl, 1-C1-6 alkylpiperidinyl, etc.; Q2 = a single bond, (un)substituted 1,4-phenylene, piperidine-1,4-diyl, thiazole-2,5-diyl, [1,3,4]thiadiazole-2,5-diyl, pyridine-2,5-diyl; Q3 = each (un)substituted Ph, thienyl, pyrrolyl, or pyridyl] or pharmacol. acceptable salts thereof were prepared These compounds have a potent inhibitory activity on activated blood coagulation factor Xa (FXa) and exhibit quick, sufficient and lasting antithrombotic effect even by oral administration. They are useful for the prevention and/or treatment of thrombus or embolism, more specifically cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary embolism, Buerger disease, deep vein thrombosis, disseminated intravascular coagulation (DIC), thrombus formation after artificial valve/joint replacement, thrombus formation or re-obstruction (clogging) after vascular reconstruction, multiple organ failure (MODS), thrombus formation during extracorporeal circulation, or blood coagulation during blood sampling. Thus, 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxylic acid hydrochloride 260, HOBt 140, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 234 mg, and 320 μL Et3N were added to a solution of 253 mg N-(2-aminobenzyl)-5-chlorothiophene-2-carboxamide in 10 mL DMF and the resulting mixture was stirred at room temperature for 23 h to give, after workup, 262 mg N-[2-[[[(5-Chlorothiophen-2-yl)carbonyl]amino]methyl]phenyl]-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamide (II). II hydrochloride and 4-[[[(5-Chlorothiophen-2-yl)carbonyl]amino]methyl]-3-fluoro-5-[[(5-isopropyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]benzoic acid Me ester (III) inhibited human FXa with IC50 of 1.7 and 0.51 nM, resp. The experimental process involved the reaction of Ethyl 3-fluoro-2-methylbenzoate(cas: 114312-57-1).Electric Literature of 114312-57-1

The Article related to angina pectoris, anticoagulants, brain infarction, diamides role: pac (pharmacological activity), spn (synthetic preparation), thu (therapeutic use), biol (biological study), prep (preparation), uses (uses), disseminated intravascular blood coagulation, embolism, homo sapiens, human, multiple organ failure, myocardial infarction, pulmonary embolism, stroke, thromboangiitis obliterans, thrombus, venous thrombosis and other aspects.Electric Literature of 114312-57-1

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On April 4, 2000, Suzuki, Nobuhiro; Takekawa, Shiro; Kubo, Keiji; Imaeda, Yasuhiro published a patent.Product Details of 29704-38-9 The title of the patent was Preparation of imidazole derivatives as gonadotropin-releasing hormone antagonists. And the patent contained the following:

Claimed are gonadotropin-releasing hormone (GnRH) antagonists containing the title compounds [I; ring A = (un)substituted Ph; ring B = (un)substituted cyclic group; R4 , R6 = H, (un)substituted C1-6 alkyl, C2-6 alkenyl, C3-7 cycloalkyl, (un)substituted C7-13 aralkyl, C2-7 alkoxycarbonyl; R5 = H, halo, (un)substituted C1-6 alkyl, C1-6 alkoxy, C2-7 alkoxycarbonyl, etc.; X = bond, C1-6 alkylene, C2-6 alkenylene, C1-6 alkylene-NHCO, C1-6 alkylene-O2NH; Y = CO, SO2, NHCO, C1-6 alkylene-CO, C2-6 alkylene-CO, C1-6 alkylene] or pharmacol. acceptable salts thereof. These compounds are useful for the treatment or prevention of gonadotropin-releasing hormone-related diseases such as sex hormone-dependent cancer, prostate cancer, uterine cancer, breast cancer, prostatic hypertrophy, true precocious puberty, endometriosis, hysteromyoma, pregnancy regulators, and menstruation regulators. Thus, 5-amino-2-(4-methoxyphenyl)benzimidazole was condensed with 4-pyrrolidinobenzoic acid using di-Et cyanophosphate in the presence of Et3N and 4-dimethylaminopyridine in DMF at room temperature for 1 h to give 41% 2-(4-methoxyphenyl)-5-((4-pyrrolidinobenzoyl)amino)benzimidazole (II). II in vitro showed IC50 of μg/mL for inhibiting the binding of [125I]leuprolelin to a membrane sample of CHO cell expressing human GnRH receptor. The experimental process involved the reaction of tert-Butyl 2-(4-nitrophenyl)acetate(cas: 29704-38-9).Product Details of 29704-38-9

The Article related to antitumor agents, benign prostatic hyperplasia, endometriosis, mammary gland neoplasm, menstruation (regulators), myoma (hysteromyoma), neoplasm (sex hormone-dependent), precocious puberty (true), pregnancy (regulators), prostate gland neoplasm, uterus neoplasm and other aspects.Product Details of 29704-38-9

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On October 31, 2019, Christia, Christina; Tang, Bin; Yin, Shan-Shan; Luo, Xiao-Jun; Mai, Bi-Xian; Poma, Giulia; Covaci, Adrian published an article.Recommanded Product: Tris(2-ethylhexyl) benzene-1,2,4-tricarboxylate The title of the article was Simultaneous determination of legacy and emerging organophosphorus flame retardants and plasticizers in indoor dust using liquid and gas chromatography-tandem mass spectrometry: method development, validation, and application. And the article contained the following:

A method was developed and validated to simultaneously detect and quantify 19 organophosphorus flame retardants (PFR/ePFR; 14 legacy, 5 emerging) and 20 plasticizers (7 legacy [LP], 13 alternative plasticizers [AP]). Sample preparation was based on combining previously validated anal. protocols, including ultrasonic extraction and Florisil fractionation/clean-up. The anal. was liquid chromatog./tandem mass spectrometry (LC/MS-MS) for all targeted compounds except bis (2-ethylhexyl) phthalate (DEHP) and bis (2-ethylhexyl) terephthalate (DEHT), for which isomer separation resulted in more favorable gas chromatog./electron ionization/mass spectrometry (GC-EI-MS) anal. This method was validated using two levels of analyte fortification in dust. Achieved linearity (R2) was 0.993-0.999. Limits of detection and quantification (LOD, LOQ) were 1-265 ng/g and 1-870 ng/g for all analytes, resp., except DEHP and DEHT, for which relatively higher LOD (665 and 1100 ng/g) and LOQ (2100 and 3500 ng/g) resp., were observed Accuracy was 75-125% for most of analytes; repeatability was good with relative standard deviation <15% for most compounds The method determined/quantified targeted analytes in house dust (n = 10) from Guangzhou, China. Median concentrations were 3-210 ng/g for PFR, 4-165 ng/g for ePFR, 30-100,000 ng/g for LP, and 6-34,000 ng/g for AP. Main contributors to total contamination were LP (63%) and AP (37%) in total plasticizers; PFR and ePFR contributed 90 and 10% of total flame retardants. The experimental process involved the reaction of Tris(2-ethylhexyl) benzene-1,2,4-tricarboxylate(cas: 3319-31-1).Recommanded Product: Tris(2-ethylhexyl) benzene-1,2,4-tricarboxylate

The Article related to environmental analysis, fire-resistant materials (organophosphorus), fireproofing agents (organophosphorus), fractionation (analyte florisil), gas chromatography (mass spectrometry and), household dust, liquid chromatography-tandem mass spectrometry, plasticizers, ultrasonication (vortexing and, extraction method) and other aspects.Recommanded Product: Tris(2-ethylhexyl) benzene-1,2,4-tricarboxylate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics